Articles

Amgen NASDAQ: AMGN pharmaceutical powerhouse just announced outstanding performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.

Study met primary endpoint of Reducing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The immediate past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being investigated for its potential to inhibit all stages of osteoclast activity by a targeted mechanism. Denosumab is being researched for a variety of bone loss conditions including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to defer bone metastases and stop and treat bone destruction across many stages of cancer.

Often referred to as the "silent epidemic", osteoporosis is a world wide problem illness, which is increasing in significance as the population of the world both ages and increases. WHO, The World Health Organization has recently identified osteoporosis as a priority health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this horrendous disease.

According to Amgen the economic burden of osteoporosis is comparable to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been developing prescriptions drugs to help patient who experience serious side effects. These products are created simultaneously the medications that aid in the treatment of the primary illness. The fact that data is available to help anticipate the possible effects and interactions drugs have with each other is outstanding.

These medicines are used to both prevent and treat osteoporosis. Some medicines increase bone thickness or slow the rate of bone loss. Even small amounts of new bone growth may diminish the risk of broken bones. It is essential that you take vitamin D and calcium, eat well and exercise when you take osteoporosis prescriptions.

prescription drug